Status:
COMPLETED
Pazopanib to Treat Adults With Advanced Cancers and Varying Degrees of Liver Function
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Neoplasms
Lymphoma
Eligibility:
All Genders
18-110 years
Phase:
PHASE1
Brief Summary
Background: * Pazopanib is an experimental drug that was designed to enter cancer cells and block the activity of proteins that are important for cancer cell growth and survival. * This is the first ...
Detailed Description
Background: * Pazopanib is a potent, multi-targeted receptor tyrosine kinase inhibitor of VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha, PDGFR-beta, and c-kit with the potential to inhibit angiogenesis, lym...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- For patients at the NCI, histological or cytological confirmation of solid tumor or lymphoma diagnosis will be performed at the NCI Laboratory of Pathology.
- EXCLUSION CRITERIA:
- Patients who have had prior treatment with pazopanib will not be eligible for this study.
- Patients with abnormal liver function except grade 4 AST, grade 4 ALT, and grade 4 bilirubin will be eligible and will be grouped according to the criteria in Section 5.1. For assessing hepatic dysfunction, greater than 35 percent of the total bilirubin must be direct bilirubin.
Exclusion
Key Trial Info
Start Date :
October 7 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 22 2013
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT00674024
Start Date
October 7 2008
End Date
January 22 2013
Last Update
November 20 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892